Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28725165 | 1.00 | SLC9A1 (0.42) | SLC9A1TDP1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL28725215 | 0.88 | AKR1C3 (0.42) | SLC9A1TDP1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL22210200 | 0.88 | AKR1C3 (0.42) | SLC9A1TDP1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL28725138 | 0.82 | SLC9A1 (0.37) | SLC9A1SMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL21353888 | 0.81 | SLC9A1 (0.38) | SLC9A1TDP1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL21353891 | 0.81 | SLC9A1 (0.38) | SLC9A1TDP1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL21363515 | 0.81 | SLC9A1 (0.38) | SLC9A1TDP1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL22194887 | 0.77 | MAPT (0.36) | SLC9A1SMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL22209972 | 0.76 | TDP1 (0.40) | TDP1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL29539745 | 0.76 | TDP1 (0.40) | TDP1SMN1; SMN2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | SLC9A1 312/4885TDP1 2634/4885SMN1; SMN2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.